GLP-1/glucagon co-agonism restores leptin responsiveness in obese mice chronically maintained on an obesogenic diet

  1. Timo D. Müller1
  1. 1 Institute for Diabetes and Obesity, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) and Technical University Munich, Munich, Germany
  2. 2 Ambrx, Inc., San Diego, CA, USA 92037
  3. 3 Institute for Diabetes and Regeneration, Helmholtz Center Munich, German Research Center for Environmental Health (GmbH) and Ludwig-Maximilian University Munich, Munich, Germany
  4. 4 Department of Chemistry, Indiana University, Bloomington, IN, US 47405
  1. *Corresponding authors: Matthias H. Tschöp, tschoep{at}helmholtz-muenchen.de, Richard D. DiMarchi, rdimarch{at}indiana.edu

Abstract

We recently reported restoration of leptin responsiveness in diet-induced obese (DIO) mice using a pharmacologically-optimized, PEGylated (PEG) leptin analog in combination with exendin-4 or FGF21. However, return of leptin action required discontinuation of high-fat diet (HFD) exposure. Here we assess whether a single peptide possessing balanced co-agonism at the GLP-1 and glucagon receptors can restore leptin responsiveness in DIO mice maintained on HFD. DIO mice were treated with PEG-GLP-1/glucagon (30 nmol/kg every fourth day) to induce a ∼15% body weight loss, once upon they were randomized to continue PEG-GLP-1/glucagon therapy or reassigned to receive supplemental daily PEG-leptin (185 nmol/kg/day). The addition of PEG-leptin to PEG-GLP-1/glucagon resulted in an ∼18% greater weight loss as compared to PEG-GLP-1/glucagon alone, and was accompanied by further decreases in food intake and improved glucose and lipid metabolism. The beneficial effect of PEG-leptin supplementation occurred after an initial body weight loss similar to what we previously reported following reduced dietary fat along with PEG-leptin and exendin-4 or FGF21 co-treatment. In summary, we report that GLP-1/glucagon co-agonism restores leptin responsiveness in mice maintained on a HFD, thus emphasizing the translational value this polypharmacotherapy for the treatment of obesity and diabetes.

  • Received October 18, 2013.
  • Accepted December 18, 2013.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

Articles citing this article

This Article

  1. Diabetes
  1. Supplementary Data
  2. All Versions of this Article:
    1. db13-1609v1
    2. 63/4/1422 most recent